This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/13/2026
Patients were enrolled into 1 of the following 3 cohorts20
Chari et al (2025)2 published the incidence of ataxia/balance disorders from a post hoc analysis of the MonumenTAL-1 study at a median follow-up of 25.6 months (IQR, 8.5-25.9) for the 0.4 mg/kg SC QW cohort, 19.4 months (IQR, 9.2-20.7) for the 0.8 mg/kg SC Q2W cohort, and 16.8 months (IQR, 7.6-18.7) for the prior TCR-exposed cohort.
| Adverse Reaction | Severity | Actions |
|---|---|---|
| Neurologic Toxicity (excluding ICANS)a | Grade 1 |
|
| Grade 2 Grade 3 (First occurrence) |
| |
| Grade 3 (Recurrent) Grade 4 |
| |
| Abbreviations: ICANS, Immune effector cell-associated neurotoxicity syndrome; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events. aBased on NCI-CTCAE Version 4.03. bFor ataxia/balance disorder perform benefit/risk assessment prior to resuming treatment with TALVEY. | ||
| Parameter, n (%) | Tal-DR (N=20) |
|---|---|
| Ataxia/balance disordersa (any grade) | 3 (15) |
| Grade 3/4 | 0 |
| Leading to the discontinuation of TALVEYb | 2 (10) |
| Events recovered or recoveringc | 4 (100) |
| Abbreviations: AE, adverse event; Tal-DR, TALVEY + DARZALEX FASPRO + lenalidomide. Note: Median follow-up: 12.5 months (range, 3.4-14.9). Data cutoff: March 2, 2026. aAtaxia/balance disorders included ataxia, dysarthria, balance disorder, nystagmus, cerebellar ataxia, cerebellar syndrome, dysmetria, and gait disturbance. bPatients could report multiple AEs that lead to the discontinuation of TALVEY. cPercent of events resolved is calculated using the total number of events for the respective AE as the denominator. Evaluated in 4 patients. | |
| Parameter | TALVEY 0.4 mg/kg QW/ 0.8 mg/kg Q2W + DARZALEX FASPRO (N=65) | TALVEY 0.4 mg/kg QW/ 0.8 mg/kg Q2W + DARZALEX FASPRO + pomalidomide (N=77) |
|---|---|---|
| Patients with ataxia/balance disorders, n (%) | 6 (9.2) | 9 (11.7) |
| Maximum toxicity grade | ||
| Grade 1 | 4 (6.2) | 6 (7.8) |
| Grade 2 | 2 (3.1) | 2 (2.6) |
| Grade 3 | 0 | 1 (1.3) |
| Grade ≥4 | 0 | 0 |
| Leading to discontinuation of TALVEY | 1 (1.5) | 1 (1.3) |
| Median time to onset from 1st dose of TALVEY, days (range) | 486.0 (42-1169) | 38.5 (2-1030) |
| Median duration, days (range)a | 42.0 (11-295) | 8.0 (1-633) |
| Number of events recovered or resolved, n (%) | 3/7 (42.9) | 7/10 (70.0) |
| Abbreviations: AE, adverse event; Q2W, every other week; QW, weekly. Note: Percentages are calculated with the number of patients in the Safety Analysis Set as the denominator, except for the outcome of events for which percentages are calculated with the number of events as the denominator. Note: AEs are reported until 100 days after the last dose of TALVEY or until the start of subsequent anticancer therapy, if earlier. Note: Time from the last injection to new onset is defined as date of the last dose – the event start date + 1. Duration is defined as the event end date – the event start date + 1. Note: Data cutoff: April 30, 2025. aIncludes events with both start and end dates available. | ||
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 26 October 2026.
| 1 | Rasche L, Schinke C, Touzeau C, et al. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. [published online ahead of print August 10, 2026]. Blood. doi:10.1182/blood.2025031994. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 |
Would you like to clear and leave your conversation? Message history will be lost.